Please assess the completion status of the following clinical trial:

Trial Title: A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-Patients with renal impairment: mild, moderate, severe and patients on hemodialysis) that has been stable OR~* Healthy Subjects:~* Have normal renal function~* No evidence of any disease or condition that may affect pharmacokinetics of FEP-TAZ.~Exclusion Criteria:~* Evidence of hepatorenal or nephritic syndrome~* Any clinically significant abnormal findings on medical history, physical examination,or clinical laboratory tests (other than those associated with controlled diabetes,hypertension, hypercholesterolemia, dyslipidemia, or renal impairment or related or causative diseases)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- FEP-TAZ (Type: EXPERIMENTAL): Cefepime and Tazobactam combination; IV infusion over a period of 90 minutes Healthy subjects, Mild and Moderate RI: 4 g (2 g FEP and 2 g TAZ) Severe RI and patients on HD: 2 g (1 g FEP and 1 g TAZ)

Based on this trial design, predict the completion outcome and termination type (if applicable).